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Abstract
Introduction: Activated protein C (APC) induces release of microparticles (MP) from primary physiological cells,
which are found in patients undergoing treatment with recombinant human APC (rhAPC) for severe sepsis. We
hypothesised that APC on these circulating MPs activate endothelial protease-activated receptor 1 (PAR1) to induce
anti-apoptotic and anti-inflammatory properties that can improve patient outcome.
Methods: This was an experimental study on clinical samples in an intensive care setting, and included patients
with severe sepsis who fulfilled criteria for treatment with rhAPC. The number of CD13+ MPs from the patients
were analysed to determine their origin. They were also quantified for endothelial protein C receptor (EPCR) and
APC expression. Clinical relevance of these MPs were ascertained by comparing survival between the group
receiving rhAPC (n = 25) and a control group of untreated patients (n = 25). MPs were also incubated with
endothelial cells to analyse apoptotic gene expression, cytoprotection and anti-inflammatory effects.
Results: rhAPC treatment induced a significant increase in circulating MP-associated EPCR by flow cytometry (P <
0.05) and by quantitative ELISA (P < 0.005). APC expression also showed significant increases (P < 0.05).
Numerically, CD13+ MPs were higher in rhAPC-treated survivors versus non-survivors. However, the number of
non-survivors was low and this was not significantly different. APC on MPs was demonstrated to induce anti-
apoptotic and endothelial barrier effects through the activation of endothelial PAR1.
Conclusions: rhAPC treatment in patients with sepsis significantly increases circulating EPCR + MPs. These MPs
were noted to express APC, which has specific anti-apoptotic and anti-inflammatory effects, with a non-significant
correlative trend towards survival. This suggests that MPs could disseminate APC function and activate endothelial
PAR1 at distal vascular sites.
Introduction
The presence of circulating microparticles (MPs) in sep-
tic patients is well recognised [1,2] and is inducible by
thrombin [3], cytokines [4], lipopolysaccharide (LPS) [5]
and collagen [6]. Derived from cell membrane shedding
as a result of activation or apoptosis, circulating MPs
constitute a marker of vascular and systemic disease [7].
Rearrangement of membrane phospholipids during MP
release can result in increased phosphatidylserine
availability with procoagulant activity. In patients with
myocardial infarction and diabetes mellitus, elevated MP
levels correlate with increased thromboembolic risk
[8,9]. However, their functional role in the pathophysiol-
ogy of sepsis remains unclear.
Elevated circulating MPs do not cause thrombosis in
healthy individuals, principally due to the protective
effects of the natural anticoagulant, activated protein C
(APC) [10]. APC is an anticoagulant [11] with anti-
inflammatory and anti-apoptotic properties [12]. These
beneficial effects may be explained by its binding to the
endothelial protein C receptor (EPCR) with cleavage of
endothelial protease activated receptor 1 (PAR1) [13].
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are not yet known, recombinant human APC (rhAPC) is
currently used to treat patients with sepsis [14]. Its cur-
rent use remains controversial because of reports of
severe bleeding complications during rhAPC treatment
[15] and a second phase 3 trial is ongoing (PROWESS
Shock) [16].
We have previously demonstrated that APC can gen-
erate MPs in vitro from EPCR-expressing cells, which
retain anticoagulant and PAR1-dependent anti-inflam-
matory properties [17]. In vivo demonstration of these
APC-MP in septic patients during rhAPC infusion [18]
led us to hypothesize that such circulating MPs may
retain their anti-inflammatory, and cytoprotective prop-
erties in these patients. An increased number of these
MPs would thus translate into clinical benefits for the
patient with severe sepsis.
Materials and methods
Circulating MP-associated EPCR
Circulating MPs were from patients diagnosed with
severe sepsis (American College of Chest Physicians cri-
teria) [19], who also fulfilled the National Institute of
Clinical Excellence (England and Wales) criteria [20] for
rhAPC (Drotrecogin alfa (activated)) (Xigris
®, Eli Lilly,
Houten, Netherlands) treatment. The type of organisms
isolated included pneumococcus, enterococcus, entero-
bacter, coagulase-negative staphylococcus and staphylo-
coccus aureus. Patients who received a 96-hour
continuous infusion of rhAPC (24 μg/kg/hr) were con-
trasted with an equal number of patients who were eligi-
ble but not treated because of concerns over bleeding
risks. These concerns included gastrointestinal bleeding
within six weeks (2), platelets < 30 × 10
9/L (6), internal
bleeding (3), intracranial pathology (1), chronic severe
liver disease (4), recent major surgery (7) and trauma
(2). None of these patients were on heparin prophylaxis
because of bleeding concerns and all rhAPC-treated
patients received low molecular weight heparin prophy-
laxis before and after but not during rhAPC infusion.
The study protocol was approved by the Local Research
Ethics Committee and the Research and Development
departments of the Royal Liverpool University Hospital
and Guy’s and St. Thomas’ Hospitals. Informed consent
was obtained from patients or when patients were
unable to consent, assent was sought from their next-of-
kin for enrolment into the study and publication of
results. Written consent was also obtained from six
healthy normal donors who provided blood samples for
MP isolation. A copy of the written consent is available
for review by the Editor-in-Chief of this journal. Blood
samples were collected into 0.105 M trisodium citrate
with and without 0.1 M benzamidine. From each
patient, this was six blood samples. In the rhAPC-
treated group, this was before rhAPC initiation and then
at 24, 48, 72 and 96 (during rhAPC infusion) and 120
hours (post-rhAPC treatment). In the non-rhAPC trea-
ted group, corresponding time points for blood sampling
were also used.
CD13 (aminopeptidase N) is a trans-membrane pro-
tease present in endothelialc e l l sa n dr e c o g n i s e da sa
marker for MPs arising from these cells. EPCR, the cel-
lular receptor for protein C and activated protein C, is
primarily localized on endothelial membrane and has
been demonstrated to be expressed on endothelial MPs.
Using fluorescence-activated cell sorting (FACS) [17],
CD13 and EPCR were enumerated from a MP-specific
gate based on size and calculated in relation to 3 μm
latex (polystyrene) beads. MPs were isolated by initial
centrifugation of plasma at 5,000 g for 10 minutes to
remove cells, followed by further centrifugation of the
s u p e r n a t e n ta t1 8 , 0 0 0gf o r3 0m i n u t e st w i c ea t4 ° C .
EPCR and APC on MPs were measured by ELISA, as
previously described [17]. In brief, MPs were captured
by anti-EPCR-RCR2 and detected using chromogen
S2366 or anti-EPCR RCR49-biotin for quantifying APC
and EPCR, respectively. All assays were performed
blinded to knowledge of rhAPC treatment or its timing.
For experiments assessing functional effects, platelet-
derived MPs were removed as these are not induced by
APC [17] by first labelling with CD41 (platelet glycopro-
tein IIb)-phycoerythrin (PE) for 15 minutes and mixed
with anti-PE magnetic beads (Miltenyi Biotech, Bisley,
Surrey, UK) for 20 minutes on ice. Wash-through was
collected for CD41-negative MPs with negativity con-
firmed by FACS. Clinical data were collected, including
baseline characteristics and outcome at 28 days.
Functional assays
In addition to the clinical studies of MP number, func-
tional assays were also performed to assess the effect of
rhAPC-expressing MPs on endothelial cell function.
Details of reagents and methods used to determine
endothelial gene expression are available in Additional
file 1. As previously reported [21,22], a 1.5-or greater
fold-change in hybridization intensity was used to
denote significant regulatory change in gene expression.
The effect of MPs on endothelial permeability was ana-
lysed in a dual chamber system using Evans Blue-
labelled bovine serum albumin (BSA) [23]. In brief,
EAhy926 cells (endothelial cell line) were plated on 6.5
mm diameter Transwell polycarbonate membranes of 3
μmp o r es i z e( C o s t a r ,C o r n i n g ,N Y ,U S A ) .U p p e ra n d
lower chambers were filled with 100 μL and 500 μLo f
growth medium, respectively. Cells were grown for two
days to obtain monolayers that were “sub-confluent”.A s
described by Feistritzer [23], the sub-confluent model
enables any improvement in endothelial barrier integrity
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nist. Blocking antibodies and inhibitors were added 30
minutes before APC or MP. Cells were exposed to APC
or MP for three hours and permeability assessed after-
wards by adding 0.67 mg/ml Evans Blue in medium
containing 4% BSA to the top chamber. After 10 min-
utes, an aliquot was taken from the lower chamber and
diluted 1:2 in medium for measurement at 650 nm.
Further studies on the influence of zymogen protein C
on APC binding to MPs [24] was based on the binding
assay of Regan et al. [25] (Supplementary Materials and
methods).
Statistical analysis
Data were expressed as the mean and standard deviation
(SD) of at least four independent experiments. For MP
quantification in Figure 1A, B, data were expressed as
the median with interquartile ranges (IQR). In data that
were not normally distributed, Mann-Whitney U tests
with Bonferroni correction were used.
Results
APC treatment in patients with sepsis induces the release
of EPCR-expressing MPs
In initial experiments on six rhAPC treated patients,
FACS demonstrated a significant increase in CD13 and
EPCR expressing MPs (P < 0.05) within 24 hours of the
treatment (Table 1). Due to sample volume limitations
from the critically ill patients and concordant informa-
tion from CD13 and EPCR expression in the available
cases, further analyses (50 patients) utilised only CD13
positivity as a marker of EPCR-expressing MPs. Table 2
highlights the characteristics of these groups along with
the APACHE II scores, sepsis aetiology, vasopressor
treatment, DIC scores, ITU stay and survival data,
which were comparable. A trend towards lower platelet
counts was, however, noted in the non-rhAPC treated
group.
Figure 1A shows that the number of CD13+ MPs was
higher (P = 0.1) in patients that underwent rhAPC infu-
sion and survived (22.7 × 10
6/ml, IQR 18.5 to 31.5)
compared to rhAPC treated non-survivors (10 × 10
6/ml,
IQR 8.2 to 28.9). The level of CD13+ MPs in the non-
rhAPC treated survivor group were not significantly dif-
ferent statistically from non-rhAPC treated non-survivor
patients (P = 0.19).
The amount of APC on the generated MPs was mea-
sured by ELISA (Figure 1B). The levels were significantly
higher during rhAPC treatment compared with indivi-
dual, pre-treatment controls and unrelated, non-rhAPC
treated patient controls (Figure 1B). In all the 25
rhAPC-treated patients, the level of APC detected in
MPs was between 120 and 350 ng/ml. Daily monitoring
showed no significant variation in levels. Levels were
higher from the rhAPC survivors (202.6 ng/ml, IQR
194.5 to 251.7) compared to the rhAPC treated non-sur-
vivors (187.5 ng/ml, IQR 160.2 to 198.4) (P = 0.04).
These data were compared with our in vitro studies
which showed that the proportion of rhAPC that is
bound to MPs following APC stimulation is approxi-
mately 6 to 10% (Additional file 2). To assess if APC on
MPs could be due to passive binding to already circulat-
ing MPs, rhAPC was added to plasma samples from
non-rhAPC-treated septic patients for 24 hours. The
results showed less than 20 ng/ml APC in these cases
(data not shown), indicating that findings during rhAPC
treatment reflect APC bound to circulating MP-asso-
ciated EPCR. Specific EPCR ELISA indicated a signifi-
cant increase of EPCR levels on MPs during rhAPC
treatment (160 ng/ml) in comparison to pre-treatment
levels (80 ng/ml) (Figure 1C). This was also demon-
strated to be not because of passive binding of sEPCR
to MPs, as sEPCR levels in MP-free plasma were
unchanged from pre- to rhAPC-treatment samples.
MP-associated EPCR from APC-treated patients express
anticoagulant activity
The functional aspects of MP released during rhAPC
treatment were next analysed. Figure 1D shows a sub-
stantial loss in thrombin generation by these MPs com-
pared with pre-treatment stage. Mean thrombin
generation fell from approximately 294 ng/ml to 184
ng/ml during rhAPC infusion. This was reversible by PC
blockade or the APC inhibitor, a1AT. By contrast,
patients not treated with rhAPC did not express this
anticoagulant property (data not shown). This indicates
that a functionally active circulating form of APC exists
on MP-EPCR during clinical treatment with rhAPC.
APC levels on MPs were observed to be similar in the
absence or presence of PC. This indicates that APC on
patients’ MPs (n = 4) are not easily displaceable as levels
in the separated supernatant remained unchanged even
at very high PC concentrations (Figure 2).
Circulating MP-associated EPCR affects APC-specific anti-
apoptotic gene expression
Since APC on MP-EPCR in plasma retain anticoagulant
activity, we postulated that they could modulate genes
involved in apoptosis and inflammation. As the majority
of circulating MPs are platelet-derived and platelets do
not express EPCR [26], these were depleted to obtain an
EPCR-enriched MP pool. The efficiency was 95 to 98%
depletion and the vast majority of these CD41-depleted
MPs were CD13 and EPCR positive (data not shown).
When these MPs (approximately 0.15 × 10
6) were tested
on gene arrays, those isolated during rhAPC treatment
induced the expression of anti-apoptotic genes including
A20, Bcl-x and the vascular endothelial growth factor
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Page 3 of 11Figure 1 The clinical correlation of activated protein C-induced MPs with survival, EPCR expression and anticoagulant properties.
Figure 1 shows the effect of rhAPC treatment on (A) CD13+ MPs, and (B) APC levels on MPs. MPs from 50 septic patients obtained on Day 1
(25 treated with rhAPC and 25 matching untreated non-rhAPC patients) were analysed by flow cytometry for CD13 positive MPs/ml of plasma.
MPs were stained with PE IgG control or CD13 antibodies. Levels of APC on the MPs were quantified using S2366 by ELISA on MPs isolated from
rhAPC-treated or non-treated patients. Survival at 28 days is denoted by + (n = 16 for both treated and untreated groups) and death by - (n =9
for both groups). ** indicates significance of P ≤0.016 by Mann-Whitney U test with Bonferroni correction. (C) Levels of EPCR expression were
measured by ELISA on MPs isolated from plasma and the residual MP-free plasma from six rhAPC treated patients (light bars) and six matching
untreated patients (dark bars) obtained on Day 0 and Day 1 (of rhAPC treatment or controlled time-point in non-rhAPC group). **P < 0.05
indicates significance difference between pre- vs. during-rhAPC as assessed by a Mann-Whitney U test. (D) APC activity on MP from six patients
on Days 1 and 4 was estimated by the ability to generate thrombin after a prior Factor Va incubation step. The MPs were also incubated with
Protein C antibody (PCAb) and a1-antitrypsin (a1AT) for assessing APC specificity, with APC plus phospholipid vesicles (APC + PCPS) as positive
control and APC plus soluble endothelial protein C receptor (sEPCR) as negative control. The mean values ± SD are from duplicate samples in
three experiments from each patient. *P < 0.05 and **P < 0.005 indicates significant comparisons between Day 0 vs. Day 1, Day 0 vs. Day 4 in
the absence and presence of PC antagonists.
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receptor (KDR) (Figure 3). In most cases, PC blockade
reversed these specific expressions (Additional file 3).
Exceptions to the expression of several anti-apoptotic
genes were matrix metalloproteinase (MMP)-2, and
MMP-1 to a lesser extent (PC blockade remained above
the 1.5 cut-off level for significant regulatory change).
Most transcript effects of APC were reversible by PAR1
antagonism with the exception of KDR. This could be
because of PAR1-independent APC effects or insuffi-
cient PAR1 inhibition under these conditions.
APC on circulating microparticles prevents apoptosis via
PAR1 activation
rhAPC-induced MPs could also inhibit apoptosis to a
similar level as free-APC through a PAR-1 dependent
mechanism (Figure 4). This cytoprotective property can
be shown to be absent with PAR1 antagonism. Panel 8
(in Figure 4) shows that PC blockade did not, however,
completely abrogate cytoprotective signals in all cells,
suggesting that other cytoprotective mechanisms may
exist in the context of rhAPC treatment. Another plausi-
ble explanation is that the MPs used were not 100%
EPCR and APC positive. Nonetheless, these results indi-
cate that circulating APC on MP-EPCR from rhAPC-
treated patients have anti-apoptotic properties that are
comparable to the free APC effect. Furthermore, this
was not observed with MPs from non-rhAPC treated
samples.
Barrier-protective effect of circulating APC-MP in a
subconfluent endothelial model is APC and PAR1
dependent
To further investigate a role for APC-MP on inflamma-
tion, the effect of free or MP-associated APC on
endothelial permeability was examined. Using MPs from
healthy donors as controls, we compared circulating
APC-MP from three patients before and during rhAPC
infusion. The same number of circulating MPs from
healthy individuals or patients were applied; that is, 1.4
×1 0
5 MPs per well. Figure 5 shows that circulating
MPs from the rhAPC treatment period reduced perme-
ability by approximately 35 to 40%, similar to free APC.
This protective effect was again APC and PAR1 depen-
dent. Notably, MPs taken from the patients before
rhAPC treatment or those taken from healthy indivi-
duals had a minor protective effect that did not reach
statistical significance. This was also neither APC- nor
PAR1-dependent.
Discussion
Our work is the first to demonstrate that APC can
induce the generation and release of MPs in vitro and in
vivo. A key finding from this study is that circulating
Table 1 CD13 and EPCR positive (+) microparticles in
response to recombinant human activated protein C
(rhAPC)
CD13+ (x 10
6/ml) EPCR+ (x 10
6/ml)
Patient No. Pre-rhAPC During rhAPC Pre-rhAPC During rhAPC
1 4.88 8.21 2.8 5.16
2 7.77 41.33 5.8 27.55
3 6.27 24.38 3.37 16.53
4 8.56 12.42 6.62 11.42
5 1.92 71.30 1.06 54.41
6 21.83 35.92 13.1 33.04
Median 7.02 30.15* 4.59 22.04*
During rhAPC indicates day 1 of treatment. *= p ≤ 0.025 comparing pre- vs.
during treatment effects using a Mann-Whitney U test with Bonferroni
correction.
Table 2 Patient characteristics
rhAPC treated
(n = 25)
Non-rhAPC controls
(n = 25)
Age, years* 70 (51 to 82) 61 (52 to 71)
Men/Women, n 13/12 14/11
PT, seconds* 17.6 (15.0 to 21.1) 18.1 (15.8 to 22.4)
PLT, × 10
9/l* 128 (55 to 218) 102 (25 to 298)
WBC, × 10
9/l* 19 (8 to 25.9) 19.3 (9.4 to 33)
APACHE II, score* 29 (25 to 35) 28 (24 to 34)
Aetiology of sepsis, n Pneumonia 16
Intra-abdominal infection 9
Pneumonia 13
Intra-abdominal infection 12
Septic shock 89
Noradrenaline, (μg/kg/minute)* 0.4 (0.2 to 0.7) 0.4 (0.2 to 0.9)
Overt DIC
+ 81 1
Total days on ITU, n* 8 (6 to 18) 18 (10 to 52)
Survival at 28 days 16 16
Numbers (n) with * indicate median values (minimum to maximum).
+ as defined by ISTH criteria [44].
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sepsis possess APC-specific functional effects. The inter-
action between these MPs with endothelial cells can
induce changes in gene expression, which translate into
inhibiting apoptosis and reducing endothelial permeabil-
ity. As these effects require PAR1 activation at the
endothelial surface by APC in an EPCR-bound confor-
mation [18], these results provide functional confirma-
tion to earlier microscopy evidence of the assembled
EPCR-APC complex on in vivo-derived MPs. Our find-
ings also indicate that APC binding to EPCR within cir-
c u l a t i n gM P si ss t a b l ea n dn o td i s p l a c e a b l eb yn o n -
activated PC.
Whilst circulating MPs in sepsis and inflammatory
conditions have been widely described, data on their
function are limited. The majority highlight pro-inflam-
matory [27,28], pro-apoptotic [29] and pro-coagulant
[30,31] potential of circulating MPs. Whilst increased
MP levels in disease states are generally associated with
adverse outcomes [32-34], Soriano reported that
endothelial MP levels were higher in survivors of severe
sepsis than in non-survivors [35]. Our findings would
support this with rhAPC treatment significantly increas-
ing endothelial-derived CD13+, EPCR+ MPs with a clin-
ical correlative trend towards improved outcome.
Expression of the functional EPCR-APC complex may
be relevant to this trend in survival benefit as such MPs
could bypass the requirement for cellular co-localisation
of EPCR and PAR1 to induce APC anti-inflammatory
and cytoprotective signaling [18]. As inflamed cell sur-
faces are EPCR deficient [36], MPs could be a vehicle
for APC to act at a distance on PAR1 in other cells.
This would reduce endothelial apoptosis and permeabil-
ity in distal vascular sites, as supported by increases in
anti-apoptotic A20 and Bcl-x with concomitantly
reduced pro-apoptotic Bax. This would also reduce
endothelial permeability as KDR up-regulation has bar-
rier protective functions [18]. Our findings that APC-
induced MPs are anticoagulant active suggest that these
MPs might contribute to the bleeding risks associated
with rhAPC treatment. No evidence of increased bleed-
ing was, however, observed in the rhAPC-treated patient
group.
Since thrombin can also cleave PAR1 to cause
endothelial barrier disruption, the question as to how
PAR1 mediates opposing effects has been debated and
further clarified. Recently, APC-PAR1-dependent pro-
tection has been demonstrated in vivo in reversing
inflammation-induced vascular leakage [37]. Such work
in physiological systems, and also work in our own
group [18], suggest that a key molecular differential is
the APC-induced interaction between EPCR and
sphingosine 1-phosphate that is important to cytoske-
leton stability [38]. EPCR is co-localised with PAR1 in
Figure 2 Effect of protein C (PC) on circulating activated protein C (APC)-induced microparticles (MPs). Levels of APC quantified by
chromogenic S2366 on MPs isolated from patients (Day 2 of rhAPC treatment) compared to separated supernatant following 30 minutes of
incubation with 0, 60 and 100 nM PC. Data represent mean values from four patients assayed in duplicate. **indicates P < 0.005 statistical
significance comparing MPs to corresponding supernatant.
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Gai-PAR1 protective signalling [38]. Gai-PAR1 recruit-
ment also modifies the inner leaflet of plasma mem-
branes and this may be mechanistically linked to MP
formation [39]. With EPCR located within these glyco-
sphingolipid-rich microdomains (rafts) and caveolae,
this provides a likely pathway for calcium-regulated
kinases and phosphatases, guanine nucleotide exchange
factors and mitogen-activated protein kinase cassettes
to form and release MP-EPCR [40]. As to thrombomo-
dulin (TM) expression on APC-induced MPs, our
investigations do not show a consistent presence (data
not shown). This is not unexpected given that the cel-
lular distribution of TM is different from EPCR [41]
and MP generation by APC is EPCR-dependent but
TM-independent.
A limitation of this study is in the numbers of rhAPC
treated patients, especially with the relatively few deaths
in the rhAPC treated group. To optimise the validity of
our findings, we were careful to control for the rhAPC
treated group with a group of patients who were equally
eligible for rhAPC treatment but who were not treated
due to clinician concern of bleeding risks. The platelet
count in this group was significantly lower (Table 2) but
should not have affected our MP findings or conclusions
as platelets do not express EPCR. In addition, we have
both inter- and intra-patient comparisons with sampling
before and during rhAPC treatment. Through this and
the comprehensive characterisation of both prognostic
and functional aspects of circulating MPs, this study has
taken a basic observational discovery along the transla-
tional pathway towards possible clinical relevance. It is
Figure 3 Effect on the differential expression of selected genes by circulating microparticles bearing activated protein C.H u m a n
umbilical vein endothelial cells were stimulated with microparticles (MPs) isolated from septic patients before (Day 0) and during (Day 1)
recombinant human activated protein C (rhAPC) infusion compared to an equivalent concentration of free APC. Bax, Bcl-x, A20 and KDR genes
were analysed by quantitative polymerase chain reaction and expressed relative to untreated cells, which were set at 1. Data from six patients
are presented as mean ± SD. *P < 0.05 denotes significant comparisons to untreated, with significant influences by protein C (PC) blockade or
antagonist T1 denoted at base of chart.
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Page 7 of 11Figure 4 Effect of circulating microparticle-bound activated protein C (MP-APC) on an endothelial model of apoptosis. Light microscopy
(X200 magnification) shows human umbilical vein endothelial cells: [1] untreated, and treated with [2] staurosporine (10 μM), [3] APC +
staurosporine, [4] MPs from pre-rhAPC treatment (Day 0), [5] MPs from pre-rhAPC treatment + staurosporine, [6] MPs during rhAPC treatment
(Day 4), [7] MPs during rhAPC treatment + staurosporine, [8] MPs during rhAPC treatment + Protein C (PC) Antibody (Ab) + staurosporine, and
[9] MPs during rhAPC treatment + antagonist T1 + staurosporine. The bar chart shows corresponding release of up-taken dye with data from six
separate experiments expressed as mean ± SD.*P < 0.05 and **P < 0.005 denote significant comparisons to untreated, with significant influences
by PC blockade or T1 denoted at base of chart.
Figure 5 Effect of free and circulating microparticle-bound activated protein C on endothelial permeability. Endothelial cells seeded
onto Transwell plates were incubated with 20 nmol/L free- activated protein C (APC) or with 1.4 × 10
5 circulating microparticles (MP), for three
hours and permeability was assessed using Evans-Blue-Bovine serum albumin. MP were obtained from Day 3 of rhAPC treatment. Specificity of
APC and protease activated receptor 1 (PAR1) was investigated by inclusion of protein C (PCAb) antibody (10 μg/mL) or PAR1 specific antibody
(ATAP2 at 20 μg/mL) for 30 minutes before incubation with APC or MPs. All experiments were performed as duplicates; n =3 .* * P < 0.006
denote statistical significance in relation to untreated baseline; ♦♦ P < 0.006 denote significance between APC or, microparticle-associated APC
(MP-APC) and blockade as assessed by a Mann-Whitney U test with Bonferroni correction.
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induced MPs, which to our knowledge is not influenced
by heparin or drugs that might have an endothelial
effect. This is because the APC effect is specifically cell
receptor-mediated, that is, via EPCR and PAR1. A lim-
itation to clinical translation is that the data may not be
applicable to the most seriously septic patients whose
mortality is much higher than in the study patients.
Our findings are the first to highlight that there is an
additional circulatory form of EPCR in human plasma,
that is, MP-EPCR, which is different from soluble EPCR.
Soluble EPCR is the cleaved, truncated form of EPCR
(45kD) that cannot facilitate APC proteolytic anticoagu-
lant activity [42]. Another novel finding is that this pro-
vides the first evidence in humans that the APC-PAR1
pathway is physiologically relevant because MP-EPCR
release is dependent on PAR1 activation by APC [17].
Whilst the relative importance of free versus MP-asso-
ciated APC remains to be clarified, free APC levels can
be variable during treatment in patients with sepsis [43].
This may be due to stability and clearance factors or
that cell-bound APC is not measured. Conversely, our
findings that MP-associated APC are stable both in
measurable levels and activities would point to physiolo-
gical and clinical relevance as bioactive effectors in
rhAPC-treated patients. This conclusion comes with the
caveat that their clinical relevance requires further
exploration, especially in larger numbers of patients
with septic shock and higher mortality.
Conclusions
In conclusion, treatment of septic patients with APC can
induce the release of MPs, which express EPCR. These
MPs exhibit similar functional aspects to endothelium-
associated EPCR by expressing anticoagulant activity,
modulating APC-related anti-apoptotic gene expression
and providing endothelial barrier protective effect
through APC bound to them.
Key messages
￿ rhAPC treatment in patients with sepsis signifi-
cantly increases the number of circulating EPCR/
CD13 expressing microparticles (MPs), with a clini-
cal correlative trend towards improved outcome.
￿ These MPs express APC, which has specific anti-
apoptotic and anti-inflammatory effects.
￿ This work suggests that MPs could disseminate
APC function and activate endothelial PAR1 at distal
vascular sites.
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